Date:
July 26, 2021
Issue #:
1629
Summary:
The sodium-glucose cotransporter 2 (SGLT2) inhibitor
dapagliflozin (Farxiga – AstraZeneca) has been
approved by the FDA for treatment of adults with
chronic kidney disease (CKD) at risk of progression
(not defined in the label). Dapagliflozin is the first
SGLT2 inhibitor to be approved in the US for treatment
of CKD.
dapagliflozin (Farxiga – AstraZeneca) has been
approved by the FDA for treatment of adults with
chronic kidney disease (CKD) at risk of progression
(not defined in the label). Dapagliflozin is the first
SGLT2 inhibitor to be approved in the US for treatment
of CKD.
